Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) EBIT Margin (2020 - 2025)

Harmony Biosciences Holdings' EBIT Margin history spans 6 years, with the latest figure at 15.82% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 1187.0% year-over-year to 15.82%; the TTM value through Dec 2025 reached 24.0%, down 269.0%, while the annual FY2025 figure was 24.0%, 269.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 15.82% at Harmony Biosciences Holdings, down from 27.35% in the prior quarter.
  • Across five years, EBIT Margin topped out at 40.25% in Q3 2023 and bottomed at 10.15% in Q3 2022.
  • The 5-year median for EBIT Margin is 30.69% (2022), against an average of 28.07%.
  • The largest annual shift saw EBIT Margin soared 7279bps in 2021 before it tumbled -2259bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 31.39% in 2021, then increased by 18bps to 37.11% in 2022, then crashed by -36bps to 23.87% in 2023, then rose by 16bps to 27.69% in 2024, then plummeted by -43bps to 15.82% in 2025.
  • Per Business Quant, the three most recent readings for HRMY's EBIT Margin are 15.82% (Q4 2025), 27.35% (Q3 2025), and 24.03% (Q2 2025).